PARIS: French pharmaceutical giant Sanofi and struggling US rival Novavax announced Friday an alliance to sell a Covid vaccine and develop another that combines with a flu shot. Under a licensing deal worth up to $1.2 billion, the companies will co-commercialise Novavax's Covid-19 vaccine worldwide, except in some countries including India, Japan and South Korea, where the US firm already has partnership agreements. Sanofi will book sales of Novavax's protein-based Covid-19 vaccine from 2025. The French group will be able to develop a combination flu-Covid vaccine using its own flu shots with the US company's Covid jab. Novavax, which is highly dependent on its Covid vaccine, raised doubts last year about its ability to continue its business.

Source: Indian Express May 10, 2024 10:46 UTC